Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SP140 ChIP-seq for Daudi and Ramos cell lines

ABSTRACT: Study of the effect of SP140 deletion on the distribution of H3K27me3 in two independent Burkitt''s Lymphoma cell lines (DAUDI and Ramos).

ORGANISM(S): Homo sapiens

PROVIDER: GSE229801 | GEO | 2024/11/21

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

SP140 ChIP-seq for Daudi and Ramos cell lines

Project description:SP140 ChIP-seq for Daudi and Ramos cell lines

| PRJNA956075 | ENA

Sp140 interactome analysis and proteomic analyis of WT vs Sp140 KO in Burkitt lynphoma

Project description:Interactomic anaysis of Sp140 in Burkitt lynphoma and proteomic analyis of WT vs Sp140 KO in Ramos cell line

2024-11-21 | PXD036287 | Pride

ChIP-seq analysis done for MBD3 before and after SP140 knockout in Ramos cells

Project description:Sp140 is a lymphocytic-restricted protein, an epigenetic reader working as a corepressor of genes implicated in inflammation and orchestrating macrophage transcriptional programs to maintain cellular identity. Reduced Sp140 expression is associated both to autoimmune diseases and blood cancer. However, the molecular mechanisms that link Sp140 altered protein levels to detrimental effects on the immune response and cellular growth, as well as the interactors through which Sp140 promotes gene silencing, remain elusive. In this work, we have applied a multi-omics approach (i.e. interactomics, ChIP-seq and proteomics) in two Burkitt lymphoma cell lines to identify both interactors and target genes of endogenous Sp140. We found that Sp140 interacts with the PRC2 and NuRD complexes and we demonstrated that Sp140 interaction with PRC2 is functional and directs H3K27me3 deposition on a set of target genes related to cellular growth and leukaemia progression.

2024-11-21 | GSE208134 | GEO

Burkitt lymphoma cells (Ramos cell line), wild type and SP140 knockout

Project description:Burkitt lymphoma cells (Ramos cell line), wild type and SP140 knockout

| PRJNA956073 | ENA

H3K27me3 ChIP-seq in Burkitt lymphoma cells (Ramos cell line), wild type and SP140 knockout

2024-11-21 | GSE218453 | GEO

H3K27me3 ChIP-seq in Burkitt lymphoma cells (Ramos cell line), wild type and SP140 knockout

Project description:H3K27me3 ChIP-seq in Burkitt lymphoma cells (Ramos cell line), wild type and SP140 knockout

| PRJNA903881 | ENA

SMG1, a Nonsense-Mediated mRNA Decay (NMD) regulator, as a therapeutic target in multiple myeloma

Project description:RNA expression was profiled in B-cell lymphoma cell lines treated with CC0483115 (CC-115) using strand-specific RNA-sequencing. The following cell lines were tested: GRANTA (mantle cell lymphoma, resistant to CC-115), JEKO (mantle cell lymphoma, sensitive), Jiyoye (Burkitt lymphoma, resistant), RAMOS (Burkitt lymphoma, sensitive), RPMI8226 (multiple myeloma (MM), sensitive), and U-266 (MM, resistant).

2020-07-01 | GSE140184 | GEO

ChIP-seq analysis done for MBD3 before and after SP140 knockout in Ramos cells

Project description:ChIP-seq analysis done for MBD3 before and after SP140 knockout in Ramos cells

| PRJNA858445 | ENA

Recruitment of MYC to target genes in ramos and mutu3 cells

Project description:Follicular lymphomas and diffuse large B-cell lymphomas have markedly different biological phenotypes and yet all originate from mature, germinal center B-cells. We hypothesized that alterations in DNA methylation patterning might help explain the clinical heterogeneity of these diseases. We report that intra- and inter-individual patient heterogeneity in cytosine methylation is associated with disease severity, and that methylation heterogeneity originates in germinal centers and is amplified during disease progression. Abnormal methylation patterns differ between chromosomal regions and depend on local gene density and the methylation status of neighboring genes. Lymphomagenic transcriptional regulators, such as BCL6, MYC and EZH2, perturb DNA methylation in a target gene-specific manner. Furthermore, aberrant epigenetic states – especially hypomethylation – tend to spread along DNA in a non-specific manner while insulator elements like CTCF inhibit such spreading. Our findings suggest mechanisms through which altered cytosine methylation contributes to the distinct phenotypes of tumors derived from mature B-cells. Identification of MYC target genes in Burkitt lymphomas by ChIP-on-chip. MYC ChIP-on-chip was done in two Burkitt Lymphoma (BL) cell lines (ramos and mutu3) in duplicate. This submission represents the ChIP-chip component of the study.

2012-11-27 | E-GEOD-31110 | biostudies-arrayexpress

RNA-seq analysis of several immortalized B cell lines (Namalwa, Daudi, Ramos, Raji, Toledo, ARH-77): Project 6 of Open Targets - Epigenomes of Cell Lines

Project description:The aim of this experiment was to characterize the gene expression of several immortalized B cell lines (Namalwa, Daudi, Ramos, Raji, Toledo, ARH-77). Two independent cultures were carried out for each of the cell lines. Cell lines were grown using supplier recommended culture methods and harvested sub-confluence in exponential growth phase. This RNA-seq experiment is being carried out as part of the Open Targets project to identify a gene expression signature of common immortalised cell lines/models. This signature will be used in combination with data from ChIP-seq experiments from the same cell lines against primary cells and tissues. The overall aim of the Open Targets Cell Line Epigenome project is to establish a systematic approach for the determination of human biological and disease relevance through the generation of transcriptomic and epigenomic data in cell lines of interest. Comparison of cell line mRNA expression and epigenome data with existing and newly generated reference data from human tissue and cell types will identify assay systems that will provide greater confidence in translating target biology and compound pharmacology to patients.

2018-06-11 | E-MTAB-6867 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data